Cytology Global Market Report 2018 – Forecast to 2022 – ResearchAndMarkets.com



[ad_1]

DUBLIN–(BUSINESS WIRE)–O "Global
Cytology Market 2018-2022 "
report has been added to ResearchAndMarkets.com
offer.

The cytology market will register a CAGR of almost 7% by 2022.

Screening for cervical cancer reduced morbidity and mortality
drastically. The Pap test is used as a screening tool for cervical
the cancer improved the detection of cervical intraepithelial neoplasia.
In addition, the prevalence of HPV-associated cancers is likely to increase
to direct the market. Therefore, a substantial increase in HPV associated
cancers drives the demand for cytology tests and testing methods.
In addition, the co-test helps to manage women who have
cell changes.

Market Overview

Cervical cancer screening awareness

Cervical cancer is most common in development and development
countries. It is primarily caused by human papillomavirus infection.
Screening for cancerous cells in the cervix is ​​mainly done by
cytology test on liquid basis and Papanicolaou test. The increasing prevalence of
of cases of cervical cancer have increased the demand for cytology tests.

Factors that affect test suitability

Poor fixation, techniques, inflammatory changes and cellular changes
related to radiation can obscure cells and cause misinterpretation
the result. This has led to false positive diagnoses that may occur
in case of pregnancy, sample contamination and others. Such
factors will affect the adequacy of the test result and, therefore, negatively
affect the market.

Competitive scenario

The global cytology market is extremely concentrated with the presence of
of few companies. This market research report will help customers identify
new opportunities for growth and designing growth strategies
providing a comprehensive analysis of competitive landscape markets
and offering information on products offered by companies.

Report Summary:

The last trend that gains force in the market is the growing
awareness and screening initiatives for HPV co-testing and screening benefits.
early diagnosis of the disease is likely to increase the demand for
marketing cytology test.

According to the report, one of the main drivers of this market is the
increasing preference for liquid cytology testing. In addition, the report
that one of the main factors impeding the growth of this market
are dying air artifacts, diagnostic traps and false negative results
that affect the overall suitability of the test, negatively impacting
the growth of the market.

Key topics addressed:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market Ecosystem

  • Market Characteristics

  • Market segmentation analysis

PART 05: MARKET DIMENSION

  • Market Sizing 2017

  • Market Size and Forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Buyers Bargaining Power

  • Bargaining power of suppliers

  • Threat of new participants

  • Threat of substitutes

  • Threat of rivalry

  • Market condition

PART 07: CUSTOMER LANDSCAPE

PART 08: MARKET SEGMENTATION BY PRODUCT

PART 09: MARKET SEGMENTATION BY THE END USER

  • End User Comparison

  • Hospitals and clinics

  • Research laboratories and academic institutes

  • Others

  • End-user market opportunity

PART 10: REGIONAL LANDSCAPE

  • Geographical targeting was mainly the word

  • Regional Comparison

  • Market Opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

  • The growing popularity of the co-test

  • Consolidation and automation of laboratories

  • Advent of cytological imaging systems

PART 14: SELLER LANDSCAPE

PART 15: SELLER ANALYSIS

  • Covered Suppliers

  • Supplier classification

  • Vendor market positioning

  • Abbott

  • BD

  • F. Hoffmann-La Roche

  • Hologic

  • Thermo Fisher Scientific

  • Trivitron Healthcare

For more information on this report, please visit https://www.researchandmarkets.com/research/977gj8/global_cytology?w=4

[ad_2]

Source link